180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
180 Life Sciences Corp. (NASDAQ:ATNF) has appointed Jay Goodman to its Board of Directors as an independent member and Audit Committee member. Goodman brings over a decade of expertise in SaaS and iGaming industries, with seven years in executive leadership. He currently serves as Sales Director for Asia Pacific and Japan at Docker, Inc. His prior experience includes roles at Confluent, Skywind Games, Dropbox, Hootsuite, and OFX. The appointment aligns with 180's strategy to expand into the online gaming market, according to Interim CEO Blair Jordan.
180 Life Sciences Corp. (NASDAQ:ATNF) ha nominato Jay Goodman nel suo Consiglio di Amministrazione come membro indipendente e membro del Comitato di Audit. Goodman porta con sé oltre un decennio di esperienza nei settori SaaS e iGaming, con sette anni in posizioni di leadership esecutiva. Attualmente ricopre il ruolo di Direttore Vendite per l'Asia Pacifico e il Giappone presso Docker, Inc. Le sue precedenti esperienze includono ruoli presso Confluent, Skywind Games, Dropbox, Hootsuite e OFX. La nomina è in linea con la strategia di 180 di espandersi nel mercato del gioco online, secondo l'Amministratore Delegato ad interim Blair Jordan.
180 Life Sciences Corp. (NASDAQ:ATNF) ha nombrado a Jay Goodman para su Junta Directiva como miembro independiente y miembro del Comité de Auditoría. Goodman aporta más de una década de experiencia en las industrias de SaaS y iGaming, con siete años en liderazgo ejecutivo. Actualmente, se desempeña como Director de Ventas para Asia Pacífico y Japón en Docker, Inc. Su experiencia previa incluye roles en Confluent, Skywind Games, Dropbox, Hootsuite y OFX. La designación está alineada con la estrategia de 180 para expandirse en el mercado de juegos en línea, según el CEO interino Blair Jordan.
180 Life Sciences Corp. (NASDAQ:ATNF)는 Jay Goodman을 독립 이사이자 감사 위원회 위원으로 이사회에 임명했습니다. Goodman은 SaaS 및 iGaming 산업에서 10년 이상의 전문성과 함께 7년간의 경영 리더십 경험을 가지고 있습니다. 그는 현재 Docker, Inc.의 아시아 태평양 및 일본 영업 담당 이사로 재직 중입니다. 그의 이전 경험으로는 Confluent, Skywind Games, Dropbox, Hootsuite, OFX에서의 역할이 포함됩니다. 이 임명은 180이 온라인 게임 시장으로의 확장을 목표로 하는 전략과 일치합니다, 임시 CEO인 Blair Jordan에 따르면.
180 Life Sciences Corp. (NASDAQ:ATNF) a nommé Jay Goodman à son Conseil d'Administration en tant que membre indépendant et membre du Comité d'Audit. Goodman apporte plus d'une décennie d'expertise dans les secteurs du SaaS et de l'iGaming, avec sept ans en leadership exécutif. Il est actuellement Directeur des Ventes pour l'Asie-Pacifique et le Japon chez Docker, Inc. Son expérience précédente inclut des rôles chez Confluent, Skywind Games, Dropbox, Hootsuite et OFX. Cette nomination s'inscrit dans la stratégie de 180 d'élargir ses activités sur le marché des jeux en ligne, selon le PDG intérimaire Blair Jordan.
180 Life Sciences Corp. (NASDAQ:ATNF) hat Jay Goodman in seinen Vorstand als unabhängiges Mitglied und Mitglied des Prüfungsausschusses berufen. Goodman bringt über ein Jahrzehnt Erfahrung in den Bereichen SaaS und iGaming mit, darunter sieben Jahre in Führungspositionen. Derzeit ist er Verkaufsleiter für den asiatisch-pazifischen Raum und Japan bei Docker, Inc. Zuvor hatte er Positionen bei Confluent, Skywind Games, Dropbox, Hootsuite und OFX inne. Die Ernennung steht im Einklang mit der Strategie von 180, in den Online-Gaming-Markt zu expandieren, so der interimistische CEO Blair Jordan.
- Strategic expansion into online gaming market indicated
- Addition of board member with relevant industry expertise
- Strengthening of corporate governance with independent director appointment
- Significant pivot from life sciences to gaming industry suggests business model uncertainty
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.
Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Docker, Inc. is a leading provider of containerization technology that enables developers to build, share, and run applications across any environment seamlessly. His prior experience includes various sales leadership roles with Confluent from early 2019 through the end of 2023, and as Managing Director for Skywind Games' Asia Pacific operations from 2016 to 2022. Mr. Goodman also has held positions with Dropbox, Hootsuite, and OFX, where he has established a strong track record in strategic sales, market expansion, and operational leadership.
Mr. Goodman was appointed as an independent member of the Board of Directors and as a member of the Company's Audit Committee, as well as positions on other committees.
"We are thrilled to welcome Mr. Goodman to our Board," said Blair Jordan, Interim CEO of 180. "His depth of experience in SaaS, coupled with his extensive background in iGaming and leadership, will be instrumental to our company's evolving strategy. As we expand into the online gaming market, his proven track record in guiding companies through rapid growth and market transitions will be invaluable."
With the addition of Mr. Goodman to its Board, 180 continues to position itself for growth and innovation in the dynamic online gaming industry.
About 180 Life Sciences Corp.
180 Life Sciences Corp. is an innovative biotechnology company that is focused on advancing breakthrough treatments. With recent moves into the online gaming sector, the Company is leveraging its expertise and new strategic appointments to capitalize on the expanding opportunities in this market.
Forward-Looking Statements
This press release includes "forward-looking statements", including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, the ability of the Company to maintain the continued listing of the Company's securities on The Nasdaq Stock Market, including that the Company is not currently in compliance with Nasdaq's continued listing standards due to its current failure to maintain a three person audit committee and/or a majority of independent directors; the Company's ability to raise funding to support its operations and commercialize its newly acquired Gaming Technology Platform; the Company's ability to commercialize its Gaming Technology Platform; the lack of experience of current management with operating a gaming company; the ability of the Company to build out or acquire a front end for the Gaming Technology Platform, and the costs and timing associated therewith; the ability of the Company to generate revenue from the Gaming Technology Platform, including timing and cost thereof; our need for significant additional funding, the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; competition in the iGaming industry; risks relating to fraud, theft or cheating; our ability to obtain and maintain licenses, and the terms thereof; our required reliance on third party cloud service providers and providers of third-party communications infrastructure, hardware and software; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; our ability to commercialize our drug candidates, if proven successful for treatment in trials; risks regarding whether the administrative processes required for the issuance of patents will be completed in a timely manner or at all; risks regarding the outcome of pharmaceutical studies, the timing and costs thereof, and the ability to obtain sufficient participants; the timing of, outcome of, and results of, clinical trials statements regarding the timing of marketing authorization application (MAA) submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and New Drug Application submissions (NDA) to the U.S. Food and Drug Administration (FDA), our ability to obtain approval and acceptance thereof, the willingness of the MHRA to review such MAA and the FDA to review such NDA, and our ability to address outstanding comments and questions from the MHRA and FDA; statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory approval of 180's drug candidates, including potential delays in the enrollment and completion of clinical trials, the costs thereof, closures of such trials prior to enrolling sufficient participants in connection therewith, issues raised by the FDA, the MHRA and the European Medicines Agency (EMA); the ability of the Company to persuade regulators that chosen endpoints do not require further validation; timing and costs to complete required studies and trials, and timing to obtain governmental approvals; 180's reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies; the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; estimates of patient populations for 180's planned products; 180's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States; current negative operating cash flows and a need for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive and may include onerous terms, increases in interest rates which may make borrowing more expensive and increased inflation which may negatively affect costs, expenses and returns; statements relating to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations; expectations with respect to future performance, growth and anticipated acquisitions; expectations regarding the capitalization, resources and ownership structure of the Company; the ability of the Company to execute its plans to develop and market products and the timing and costs of these programs; estimates of the size of the markets for the Company's planned products; the outcome of current litigation involving the Company; potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company or lawsuits alleging that we have violated the intellectual property of others; global economic conditions; geopolitical events and regulatory changes; and the effect of changing interest rates and inflation, economic downturns and recessions, declines in economic activity or global conflicts. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and future SEC filings. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the "Investors", "SEC Filings", "All SEC Filings" page of our website at www.180lifesciences.com. All subsequent written and oral forward-looking statements concerning the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise provided by law.
Investor Contact:
Blair Jordan
Interim Chief Executive Officer
Email address: bjordan@180lifesciences.com
SOURCE: 180 Life Sciences Corp.
View the original press release on accesswire.com
FAQ
Who is the new board member appointed to 180 Life Sciences (ATNF)?
What is 180 Life Sciences (ATNF) new strategic direction?